Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Citius Oncology ( (CTOR) ) is now available.
On May 5, 2026, Citius Oncology secured up to $36.5 million in combined debt and equity-related capital to support the commercialization of LYMPHIR, its recently launched cutaneous T‑cell lymphoma therapy. The financings are aimed at funding sales-force expansion, market access initiatives, medical affairs and manufacturing supply chain support, as well as general working capital needs.
The company entered into a senior secured loan facility with Avenue Venture Opportunities Fund II providing up to $25 million through 2027, alongside associated lender warrants and a conversion feature into common stock. Concurrently, Citius struck a warrant inducement deal with a healthcare-focused institutional investor, generating about $11.5 million in gross proceeds via immediate exercise of existing warrants at a reduced price, offset by the issuance of new warrants and amended December 2025 warrants, a structure that bolsters liquidity but also increases potential future equity dilution.
The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn implying funding risk). Technicals are only mildly positive and remain below key longer-term averages. Corporate events provide some upside from LYMPHIR progress but are tempered by Nasdaq non-compliance risk, while valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Citius Oncology, Inc. is a Nasdaq-listed specialty biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. The company’s lead product, LYMPHIR (denileukin diftitox-cxdl), is an FDA-approved targeted immune therapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, addressing what it views as an underserved U.S. market exceeding $400 million.
Citius acquired global rights to denileukin diftitox in most markets outside parts of Asia in 2021 and launched LYMPHIR in the U.S. in December 2025. The company cites orphan-drug protections, complex technology, trade secrets and pending patents, including for combination use with checkpoint inhibitors, as key elements underpinning its competitive positioning in oncology.
Average Trading Volume: 249,935
Technical Sentiment Signal: Sell
Current Market Cap: $81.21M
For an in-depth examination of CTOR stock, go to TipRanks’ Overview page.